Business Description
Nexentis Technologies Inc. is an Israel-based company founded in 2009 that uses artificial intelligence and data tools to discover and develop small-molecule drug candidates, with a primary focus on hard-to-treat cancers and inflammatory metabolic diseases. Its core drug discovery work targets a specific family of mitochondrial proteins and is supported by early-stage research showing promising results in human-relevant models. The company also holds investments in solar energy projects across several European Union countries and offers treatment technologies that help reduce harmful pathogens in fresh produce. Formerly known as N2OFF Inc., Nexentis serves customers across the biotech, pharmaceutical, renewable energy, and agricultural industries.
